Evaluation of Efficacy and Safety of Immunotherapy Combinations Including Atezolizumab, Bevacizumab, and Tiragolumab in Metastatic Pancreatic Ductal Adenocarcinoma
- Trial ID
- 2024-511271-15-00
- Protocol
- WO39608
- Sponsor
- F. Hoffmann-La Roche AG
Register record, history and transparency: CTIS.eu
Trial statistics
Diseases & Conditions
Objectives
The primary objective of this study is to evaluate the **efficacy** of immunotherapy-based treatment combinations in patients with metastatic pancreatic ductal adenocarcinoma. This is clinically relevant as it aims to determine the potential of these combinations to improve patient outcomes in a condition known for its poor prognosis and limited treatment options.
Secondary objectives include:
- Evaluating the efficacy in terms of progression-free survival, overall survival, overall survival at specific timepoints, duration of response, and disease control.
- Assessing the safety of the immunotherapy-based treatment combinations.
Participants
The clinical trial involves a total of **253 participants** diagnosed with **pancreatic ductal adenocarcinoma (PDAC)**. The study population includes both male and female subjects, with an age range that encompasses adults and older adults. Participants were selected based on specific criteria, including a histologically or cytologically confirmed diagnosis of metastatic PDAC. The trial includes individuals who have not received prior systemic treatment for PDAC, as well as those who have experienced disease progression during first-line chemotherapy. The health status of participants requires adequate hematologic and end-organ function. The trial population also includes a vulnerable population, indicating a careful consideration of ethical standards in participant selection. Lifestyle factors such as diet, physical activity, and habits are not specified in the available data.
Plans and Procedures
The clinical trial is designed to evaluate the efficacy and safety of multiple immunotherapy-based treatment combinations in patients with **metastatic pancreatic ductal adenocarcinoma** (PDAC). This is a Phase Ib/II, open-label, multicenter, randomized umbrella study. The trial involves the administration of various investigational products, including **paclitaxel albumin-bound**, **gemcitabine hydrochloride**, **tocilizumab**, **bevacizumab**, **atezolizumab**, and **tiragolumab**, all delivered via intravenous infusion. The study is expected to conclude by August 30, 2025, with recruitment having commenced on December 22, 2017.
Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to confirm eligibility based on criteria such as histologically or cytologically confirmed metastatic PDAC, measurable disease according to RECIST version 1.1, and adequate hematologic and end-organ function. The trial will include follow-up visits to monitor the primary endpoint of objective response and secondary endpoints such as progression-free survival, overall survival, duration of response, disease control, and the incidence and severity of adverse events. The end-of-study visit will assess the overall outcomes and any changes from baseline in vital signs, ECG parameters, and clinical laboratory test results.
The expected length of participant involvement will vary depending on individual response and disease progression, with conditions for early termination including significant adverse events or withdrawal of consent. The trial's randomized design ensures that participants are assigned to different treatment arms without bias, and the open-label nature allows for the observation of treatment effects in real-time. The study aims to provide valuable insights into the potential benefits of immunotherapy combinations in treating metastatic PDAC.
Treatment
The clinical trial involves the administration of several experimental medications, each with specific pharmaceutical forms, dosages, and routes of administration. **Abraxane** is provided as a 5 mg/ml powder for dispersion for infusion, containing the active substance **paclitaxel albumin-bound**. It is administered intravenously. This formulation is a chemotherapy agent from the taxane family, specifically relabeled for clinical trial use by Bristol-Myers Squibb Pharma EEIG.
**Gemcitabin-GRY** is a 1000 mg powder for the preparation of an infusion solution, containing **gemcitabine hydrochloride**. It is administered intravenously. Gemcitabine acts by replacing cytidine during DNA replication in tumor cells, leading to apoptosis. This product is re-packaged and re-labeled for clinical trial use by Teva GmbH.
**RoActemra** is a 20 mg/mL concentrate for solution for infusion, containing the active substance **tocilizumab**. It is administered via IV infusion. This product is secondary packaged and labeled for clinical trial use by Roche Registration GmbH.
**Gemcitabin AqVida** is a 38 mg/ml powder for the preparation of an infusion solution, containing **gemcitabine**. It is administered intravenously. Similar to Gemcitabin-GRY, it induces apoptosis by replacing cytidine during DNA replication. This product is re-packaged and re-labeled for clinical trial use by AqVida GmbH.
**Gemcitabin Kabi** is another formulation of **gemcitabine** at 38 mg/ml, provided as a powder for infusion solution preparation. It is administered intravenously and functions similarly to other gemcitabine formulations in the study. This product is re-packaged and re-labeled for clinical trial use by Fresenius Kabi Deutschland GmbH.
**Avastin** is a 25 mg/ml concentrate for solution for infusion, containing **bevacizumab**. It is administered via IV infusion. This product is relabeled for clinical trial use by Roche Registration GmbH.
**Atezolizumab** is provided as a solution for infusion, containing the active substance **atezolizumab**. It is administered via IV infusion. This product is used in its standard form without additional clinical trial-specific modifications.
**Tiragolumab** is a concentrate for solution for infusion, containing the active substance **tiragolumab**. It is administered via IV infusion. This product is provided by F. Hoffmann-La Roche Ltd and is used in its standard form for the trial.
Participant compliance with the dosing schedule is monitored throughout the trial to ensure adherence to the treatment protocol. Each medication is administered according to its specific pharmaceutical form and route, with careful attention to the preparation and infusion procedures as outlined in the study protocol.
Efficacy
The efficacy of the clinical trial will be assessed using a combination of primary and secondary endpoints. The primary endpoint is the **objective response**, which will be evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Secondary endpoints include progression-free survival, overall survival, overall survival at specific timepoints, duration of response, disease control, and the incidence, nature, and severity of adverse events and laboratory abnormalities. Additionally, changes from baseline in vital signs, ECG parameters, and targeted clinical laboratory test results will be monitored.
Data collection will occur at predefined intervals throughout the study, with specific timepoints for assessment not explicitly detailed. The trial will involve the use of immunotherapy-based treatment combinations in patients with metastatic pancreatic ductal adenocarcinoma. The study aims to provide comprehensive data on the efficacy and safety of these treatment regimens, contributing to the understanding of their potential benefits in this patient population.
Inclusion and Exclusion Criteria
Inclusion Criteria
- Histologically or cytologically confirmed metastatic PDAC
- For patients in Cohort 1: no prior systemic treatment for PDAC
- For patients in Cohort 2: disease progression during administration of either 5-fluorouracil or gemcitabine-based first-line chemotherapy in the metastatic or locally advanced setting and, for patients treated in the locally advanced setting, occurrence of metastasis within 6 months after initiation of chemotherapy
- Availability of a representative tumor specimen that is suitable for determination of programmed death-ligand 1 (PD-L1) and/or additional biomarker status via central testing
- Measurable disease (at least one target lesion) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- Adequate hematologic and end-organ function test results
Exclusion Criteria
- Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.
- History of leptomeningeal disease
- Active or history of autoimmune disease or immune deficiency
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan
- Positive HIV test at screening or at any time prior to screening
- Active hepatitis B or C virus infection or active tuberculosis
Trial Status by Country
| Country | Status | Start of Recruitment | Planned Patients |
|---|---|---|---|
Spain | Not Recruiting | 22 Dec 2017 | 29 |
Sites & Investigators
Investigational Products
Details about the medicinal products being studied in this clinical trial.
| Product Name | Role in Trial | Formulation | Administration | Max Daily Dose | Treatment Duration | EU MP Number |
|---|---|---|---|---|---|---|
Abraxane 5 mg/ml powder for dispersion for infusion. | Comparator | POWDER FOR DISPERSION FOR INFUSION | INTRAVENOUS | — | — | PRD9254301 |
Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung | Comparator | PULVER ZUR HERSTELLUNG EINER INFUSIONSLÖSUNG | INTRAVENOUS | — | — | PRD472665 |
RoActemra 20 mg/mL concentrate for solution for infusion | Test | CONCENTRATE FOR SOLUTION FOR INFUSION | IV INFUSION | — | — | PRD2154622 |
Gemcitabin AqVida 38 mg/ml Pulver zur Herstellung einer Infusionslösung | Comparator | PULVER ZUR HERSTELLUNG EINER INFUSIONSLÖSUNG | INTRAVENOUS | — | — | PRD1744676 |
Gemcitabin Kabi 38 mg/ml Pulver zur Herstellung einer Infusionslösung | Comparator | PULVER ZUR HERSTELLUNG EINER INFUSIONSLÖSUNG | INTRAVENOUS | — | — | PRD707659 |
Avastin 25 mg/ml concentrate for solution for infusion. | Test | CONCENTRATE FOR SOLUTION FOR INFUSION | IV INFUSION | — | — | PRD2153902 |
ATEZOLIZUMAB | Test | — | IV INFUSION | — | — | SUB178312 |
Tiragolumab | Test | CONCENTRATE FOR SOLUTION FOR INFUSION | IV INFUSION | — | — | PRD7846761 |

